- Home
- Publications
- Publication Search
- Publication Details
Title
Cabozantinib: A Multitargeted Oral Tyrosine Kinase Inhibitor
Authors
Keywords
-
Journal
PHARMACOTHERAPY
Volume 38, Issue 3, Pages 357-369
Publisher
Wiley
Online
2017-12-28
DOI
10.1002/phar.2076
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor–Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial
- (2017) Maria E. Cabanillas et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
- (2017) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry
- (2017) Oliver Gautschi et al. JOURNAL OF CLINICAL ONCOLOGY
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Systemic Therapy for Metastatic Renal-Cell Carcinoma
- (2017) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity
- (2017) Akash Patnaik et al. Cancer Discovery
- A phase Ib/II study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC).
- (2017) H. A. Wakelee et al. JOURNAL OF CLINICAL ONCOLOGY
- Population pharmacokinetic/pharmacodynamic modeling of tumor growth kinetics in medullary thyroid cancer patients receiving cabozantinib
- (2016) Dale R. Miles et al. ANTI-CANCER DRUGS
- Clinical Pharmacokinetics and Pharmacodynamics of Cabozantinib
- (2016) Steven A. Lacy et al. CLINICAL PHARMACOKINETICS
- Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1
- (2016) Matthew Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
- (2016) Toni K Choueiri et al. LANCET ONCOLOGY
- Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer
- (2015) A. Varkaris et al. CLINICAL CANCER RESEARCH
- Novel drugs in clinical development for hepatocellular carcinoma
- (2015) Oliver Waidmann et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- MET inhibitors for treatment of advanced hepatocellular carcinoma: A review
- (2015) Xing-Shun Qi WORLD JOURNAL OF GASTROENTEROLOGY
- A phase I study of cabozantinib (XL184) in patients with renal cell cancer
- (2014) T. K. Choueiri et al. ANNALS OF ONCOLOGY
- A Novel Multiple Tyrosine-kinase Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Solid Tumors: Cabozantinib
- (2014) Subhajit Roy et al. Anti-Cancer Agents in Medicinal Chemistry
- c-MET Inhibitors in the Treatment of Lung Cancer
- (2014) Joanna Goździk-Spychalska et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Cabozantinib: A Review of Its Use in Patients with Medullary Thyroid Cancer
- (2014) Sheridan M. Hoy DRUGS
- Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study
- (2014) Matthew R. Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- Preclinical Evaluation of Imaging Biomarkers for Prostate Cancer Bone Metastasis and Response to Cabozantinib
- (2014) Timothy J. Graham et al. JNCI-Journal of the National Cancer Institute
- Combination Strategy Targeting VEGF and HGF/c-met in Human Renal Cell Carcinoma Models
- (2014) E. Ciamporcero et al. MOLECULAR CANCER THERAPEUTICS
- Understanding, recognizing, and managing toxicities of targeted anticancer therapies
- (2013) Grace K. Dy et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Cabozantinib: a novel agent with a dual mechanism of action for castration-resistant prostate carcinoma
- (2013) Álvaro Pinto CANCER CHEMOTHERAPY AND PHARMACOLOGY
- The emerging role of MET/HGF inhibitors in oncology
- (2013) Giorgio V. Scagliotti et al. CANCER TREATMENT REVIEWS
- Cabozantinib Inhibits Prostate Cancer Growth and Prevents Tumor-Induced Bone Lesions
- (2013) Jinlu Dai et al. CLINICAL CANCER RESEARCH
- A Dose-Ranging Study of Cabozantinib in Men with Castration-Resistant Prostate Cancer and Bone Metastases
- (2013) R. J. Lee et al. CLINICAL CANCER RESEARCH
- MET As a Possible Target for Non–Small-Cell Lung Cancer
- (2013) Ahad A. Sadiq et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib in Progressive Medullary Thyroid Cancer
- (2013) Rossella Elisei et al. JOURNAL OF CLINICAL ONCOLOGY
- c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma
- (2012) G. T. Gibney et al. ANNALS OF ONCOLOGY
- Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial
- (2012) David C. Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
- (2011) Razelle Kurzrock et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
- (2011) F. M. Yakes et al. MOLECULAR CANCER THERAPEUTICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started